- Home
- SPRO
as 07-08-2024 4:00pm EST
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 84.6M | IPO Year: | 2017 |
| Target Price: | $7.00 | AVG Volume (30 days): | 162.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $1.89 | Next Earning Date: | 08-08-2024 |
| Revenue: | $110,978,000 | Revenue Growth: | 107.40% |
| Revenue Growth (this year): | -73.08% | Revenue Growth (next year): | 25.72% |
Stock Insider Trading Activity of Spero Therapeutics Inc. (SPRO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mahadevia Ankit | SPRO | Director | Feb 2 '24 | Sell | $1.37 | 63,795 | $87,399.15 | 744,997 | SEC Form 4 |
| Keutzer Timothy | SPRO | Chief Operating Officer | Feb 1 '24 | Sell | $1.36 | 30,971 | $42,120.56 | 534,050 | SEC Form 4 |
| JOSEPH TAMARA L | SPRO | Chief Legal Officer | Feb 1 '24 | Sell | $1.37 | 30,906 | $42,341.22 | 531,615 | SEC Form 4 |
| HAMED KAMAL | SPRO | Chief Medical Officer | Feb 1 '24 | Sell | $1.37 | 28,075 | $38,462.75 | 788,117 | SEC Form 4 |
| Shukla Sath | SPRO | CEO and President | Feb 1 '24 | Sell | $1.37 | 30,901 | $42,334.37 | 1,221,100 | SEC Form 4 |
| Shukla Sath | SPRO | CEO and President | Feb 1 '24 | Sell | $1.45 | 45,093 | $65,384.85 | 1,176,007 | SEC Form 4 |
Latest Spero Therapeutics Inc. News
SPRO Breaking Stock News: Dive into SPRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zacks
14 days ago
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
GlobeNewswire
a month ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire
2 months ago
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Simply Wall St.
2 months ago
Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago
GlobeNewswire
2 months ago
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
GlobeNewswire
2 months ago
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRO Spero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.